Differential effects of antipsychotic agents on obsessive - Compulsive symptoms in schizophrenia: A longitudinal study

Journal of Psychopharmacology

Volumn 27, Issue 4, 2013, Pages 349-357

  Schirmbeck, Frederike ^a   Rausch, Franziska ^a   Englisch, Susanne ^a   Eifler, Sarah ^a   Esslinger, Christine ^b   Meyer Lindenberg, Andreas ^a   Zink, Mathias ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Antipsychotic agents; clozapine; comorbidity; compulsion; obsession; OCS; schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CITALOPRAM; CLOZAPINE; ESCITALOPRAM; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CALGARY DEPRESSION SCALE; CLINICAL GLOBAL IMPRESSION SCALE; COMORBIDITY; COMPULSIVE PERSONALITY DISORDER; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DEPRESSION; DISEASE SEVERITY; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSESSIVE COMPULSIVE DISORDER; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

ADULT; ANTIPSYCHOTIC AGENTS; COMORBIDITY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OBSESSIVE BEHAVIOR; PATIENT DROPOUTS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 84875720401     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881112463470     Document Type: Article

References (56)

1. Achim AM, Maziade M, Raymond E, et al. How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr Bull. 2011 ; 37: 811-821
2. Asenjo Lobos C, Komossa K, Rummel-Kluge C, et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010 ; 11: CD006633
3. Baker RW, Chengappa KN, Baird JW, et al. Emergence of obsessive compulsive symptoms during treatment with clozapine. J Clin Psychiatry. 1992 ; 53: 439-442
4. Bloch MH, Landeros-Weisenberger A, Kelmendi B, et al. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006 ; 11: 622-632
5. Bradford Hill A. The environment and disease: association or causation?. Bull World Health Org. 2011 ; 83: 295-300
6. Buckley PF, Miller BJ, Lehrer DS, et al. Psychiatric comorbidities and schizophrenia. Schizophr Bull. 2009 ; 35: 383-402
7. Chang JS, Ahn Y-M, Park HJ, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008 ; 69: 720-731
8. Connor KM, Payne VM, Gadde KM, et al. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry. 2005 ; 66: 49-51
9. Cunill R, Castells X, Simeon D. Relationships between obsessive-compulsive symptomatology and severity of psychosis in schizophrenia: a systematic review and meta-analysis. J Clin Psychiatry. 2009 ; 70: 70-82
10. de Haan L, Beuk N, Hoogenboom B, et al. Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. J Clin Psychiatry. 2002 ; 63: 104-107
11. de Haan L, Hoogenboom B, Beuk N, et al. Obsessive-compulsive symptoms and positive, negative, and depressive symptoms in patients with recent-onset schizophrenic disorders. Can J Psychiatry. 2005 ; 50: 519-524
12. de Haan L, Hoogeboom B, Beuk N, et al. Reliability and validity of the Yale-Brown Obsessive-Compulsive Scale in schizophrenia patients. Psychopharmacol Bull. 2006 ; 39: 25-30
13. de Haan L, Linszen DH, Gorsira R. Clozapine and obsessions in patients with recent-onset schizophrenia and other psychotic disorders. J Clin Psychiatry. 1999 ; 60: 364-365
14. de Haan L, Oekeneva A, van AT, et al. Obsessive-compulsive disorder and treatment with clozapine in 200 patients with recent-onset schizophrenia or related disorders. Eur Psychiatry. 2004 ; 19: 524
15. de Haan L, Sterk B, Wouters L, et al. The 5-year course of obsessive-compulsive symptoms and obsessive-compulsive disorder in first-episode schizophrenia and related disorders. Schizophr Bull. 2011 ;:
16. Dold M, Aigner M, Lanzenberger R, et al. Efficacy of antipsychotic augmentation therapy in treatment-resistant obsessive-compulsive disorder - a meta-analysis of double-blind, randomised, placebo-controlled trials. Fortschr Neurol Psychiatr. 2011 ; 79: 453-466
17. Englisch S, Esslinger C, Inta D, et al. Clozapine-induced obsessive compulsive syndromes improve in combination with aripiprazole. Clin Neuropharmacol. 2009 ; 32: 227-229
18. Erbfelder E, Faul F, Buchner A. GPOWER: A general power analysis program. Behav Res Methods Instrum Comput. 1996 ; 28: 1-11
19. Fenton WS, McGlashan TH. The prognostic significance of obsessive-compulsive symptoms in schizophrenia. Am J Psychiatry. 1986 ; 143: 437-441
20. Fontenelle LF, Lin A, Pantelis C, et al. A longitudinal study of obsessive-compulsive disorder in individuals at ultra-high risk for psychosis. J Psychiatr Res. 2011 ; 45: 1140-1145
21. Gardner DM, Murphy AL, O'Donnell H, et al. International consensus study of antipsychotic dosing. Am J Psychiatry. 2011 ; 167: 686-693
22. Hwang MY, Kim SW, Yum SY, et al. Management of schizophrenia with obsessive-compulsive features. Psychiatr Clin North Am. 2009 ; 32: 835-851
23. Joober R, Boksa P. Clozapine: a distinct, poorly understood and under-used molecule. J Psychiatry Neurosci. 2010 ; 35: 147-149
24. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988 ; 45: 789-796
25. Kang X, Simpson GM. Clozapine: more side effects but still the best antipsychotic. J Clin Psychiatry. 2010 ; 71: 982-983
26. Kim SW, Shin IS, Kim JM, et al. Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: an open-label switch study. J Clin Psychopharmacol. 2008 ; 28: 349-352
27. Klepsch R, Zaworka W, Hand I, et al Hamburger Zwangsinventar-Kurzform (HZI-K). Goettingen: Beltz TestGmbH ; 1993 :
28. Koran LM, Hanna GL, Hollander E, et al. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry. 2007 ; 164: 5-53
29. Kwon JS, Joo YH, Nam HJ, et al. Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics-induced obsessive-compulsive symptoms. Arch Gen Psychiatry. 2009 ; 66: 1233-1241
30. Lin SK, Su SF, Pan CH. Higher plasma drug concentration in clozapine-treated schizophrenic patients with side effects of obsessive/compulsive symptoms. Ther Drug Monit. 2006 ; 28: 303-307
31. Lykouras L, Alevizos B, Michalopoulou P, et al. Obsessive-compulsive symptoms induced by atypical antipsychotics. A review of the reported cases. Prog Neuropsychopharmacol Biol Psychiatry. 2003 ; 27: 333-346
32. Lysaker PH, Whitney KA. Obsessive-compulsive symptoms in schizophrenia: prevalence, correlates and treatment. Expert Rev Neurother. 2009 ; 9: 99-107
33. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006 ; 163: 600-610
34. Mukhopadhaya K, Krishnaiah R, Taye T, et al. Obsessive-compulsive disorder in UK clozapine-treated schizophrenia and schizoaffective disorder: a cause for clinical concern. J Psychopharmacol. 2009 ; 23: 6-13
35. Muscatello MR, Bruno A, Pandolfo G, et al. Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2011 ; 31: 174-179
36. Niendam TA, Berzak J, Cannon TD, et al. Obsessive compulsive symptoms in the psychosis prodrome: correlates of clinical and functional outcome. Schizophr Res. 2009 ; 108: 170-175
37. Ohoyama K, Yamamura S, Hamaguchi T, et al. Effect of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortex. Eur J Pharmacol. 2011 ; 653: 47-57
38. Poyurovsky M, Weizman A, Weizman R. Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment. CNS Drugs. 2004 ; 18: 989-1010
39. Poyurovsky M, Zohar J, Glick I, et al. Obsessive-compulsive symptoms in schizophrenia: implications for future psychiatric classifications. Compr Psychiatry. 2012 ; 53: 480-483
40. Reznik I, Yavin I, Stryjer R, et al. Clozapine in the treatment of obsessive-compulsive symptoms in schizophrenia patients: a case series study. Pharmacopsychiatry. 2004 ; 37: 52-56
41. Rocha FL, Hara C. Benefits of combining aripiprazole to clozapine: Three case reports. Progr Neuropsychopharmacol Biol Psychiatry. 2006 ; 30: 1167-1169
42. Rosa-Alcazar AI, Sanchez-Meca J, Gomez-Conesa A, et al. Psychological treatment of obsessive-compulsive disorder: A meta-analysis. Clin Psychol Rev. 2008 ; 28: 1310-1325
43. Ryu S, Oh S, Cho EY, et al. Interaction between genetic variants of DLGAP3 and SLC1A1 affecting the risk of atypical antipsychotics-induced obsessive-compulsive symptoms. Am J Med Genet. 2011 ; 156: 949-959
44. Scatton B, Claustre Y, Cudennec A, et al. Amisulpride: from animal pharmacology to therapeutic action. Int Clin Psychopharmacol. 1997 ; 12: S29 - S36
45. Schirmbeck F, Esslinger C, Rausch F, et al. Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia. Psychol Med. 2011 ; 41: 2361-2374
46. Schirmbeck F, Nieratschker V, Frank J, et al. Polymorphisms in the glutamate transporter gene SLC1A1 and obsessive compulsive symptoms induced by second generation antipsychotic agents. Psychiatr Genet. 2012 ; 22: 245-252
47. Schirmbeck F, Zink M. Clozapine-induced obsessive-compulsive symptoms in schizophrenia: A critical review. Curr Neuropharmacol. 2012 ; 10: 88-95
48. Sevincok L, Akoglu A, Kokcu F. Suicidality in schizophrenic patients with and without obsessive-compulsive disorder. Schizophr Res. 2007 ; 90: 198-202
49. Sparshatt A, Taylor D, Patel MX, et al. A systematic review of aripiprazole - dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry. 2010 ; 71: 1447-1456
50. Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009 ; 374: 620-627
51. Villari V, Frieri T, Fagiolini A. Aripiprazole augmentation in clozapine-associated obsessive-compulsive symptoms. J Clin Psychopharmacol. 2011 ; 31: 375-376
52. Westphal K. Ueber Zwangsvorstellungen. Arch Psychiatr Nervenkr. 1878 ; 8: 734-750
53. Woody SR, Steketee G, Chambless DL. Reliability and validity of the Yale-Brown Obsessive-Compulsive Scale. Behav Res Ther. 1995 ; 33: 597-605
54. Yang KC, Su TP, Chou YH. Effectiveness of aripiprazole in treating obsessive compulsive symptoms. Progr Neuropsychopharmacol Biol Psychiatry. 2008 ; 32: 585-586
55. Zink M, Englisch S, Knopf U, et al. Augmentation of clozapine with valproic acid for clozapine-induced obsessive compulsive symptoms. Pharmacopsychiatry. 2007 ; 40: 202-203
56. Zink M, Knopf U, Kuwilsky A. Management of clozapine-induced obsessive compulsive symptoms in a man with schizophrenia. Austr NZ J Psychiatry. 2006 ; 41: 293-294